FDA Pushing Generic Biologics Timetable In Election Year; "Structure" Expected Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting Commissioner Crawford's remarks on the feasibility of generic biologics reflect FDA's growing confidence that it can develop an approval pathway, after years of considering the issue too complex. He will testify on the issue during a Senate subcommittee hearing April 1.
You may also be interested in...
Follow-On Biologics Guidance Delayed, Agency Tells BIO
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.
Follow-On Biologics Guidance Delayed, Agency Tells BIO
Broad scope and broad "interest" in the topic mean it will take FDA longer than expected to complete work on the highly anticipated guidance, Acting Deputy Commissioner Woodcock says. The guidance will include an "inventory" of different ways protein products have been regulated by the agency.
Generic Biologics Approval Process Is Focus Of Employers' Coalition
Coalition formed in 2003 to push Medicare Rx bill is preparing for a legislative effort next year on generic biologics. Group also wants $75 mil. budgeted for AHRQ drug comparison research.